A new study finds the diabetes drug metformin doesn’t help patients with a type of pancreatic cancer, as evidence formerly suggested. Researchers examined the medical records of 1,360 patients with pancreatic ductal adenocarcinoma, some of whom took metformin. The median number of survival days for those who didn’t take the drug was 308 days, compared to 292 days for those who did proving that the drug didn’t give any survival benefits. Via U.S. News & World Report. Posted April 21, 2015.